MedPath

FDA Approves Arthroscopic Delivery for MACI Knee Cartilage Repair

• The FDA has approved a supplemental Biologics License Application for arthroscopic delivery of MACI, an autologous cultured chondrocytes on a porcine collagen membrane, for knee cartilage repair. • This approval expands MACI's delivery options, offering a less invasive arthroscopic approach for repairing symptomatic cartilage defects up to 4 cm2. • MACI Arthro is the only restorative biologic cartilage repair product approved for arthroscopic administration, potentially increasing market penetration. • Vericel Corporation anticipates that MACI Arthro will support sustained revenue growth by addressing a larger segment of the treatable market.

The FDA has granted approval for a supplemental Biologics License Application, allowing for the arthroscopic delivery of MACI (autologous cultured chondrocytes on porcine collagen membrane) in the repair of knee cartilage defects. This approval provides a less invasive option for surgeons and patients seeking to address symptomatic, full-thickness cartilage damage.

MACI Arthro: A Less Invasive Approach

Vericel Corporation, the manufacturer of MACI, announced that the approval covers the arthroscopic delivery of MACI to repair single or multiple full-thickness cartilage defects of the knee, up to 4 cm2 in size. MACI is an autologous cellularized scaffold product, utilizing tissue engineering to grow cells on scaffolds using healthy cartilage tissue harvested from the patient's own knee.
According to Vericel, MACI Arthro allows surgeons to evaluate and prepare the defect site and deliver the MACI implant through small incisions using custom-designed instruments. This contrasts with the existing method of administration, offering a less invasive technique.

Impact and Market Potential

Nick Colangelo, CEO of Vericel, stated, "The approval of MACI Arthro represents another significant milestone in our strategy to provide innovative solutions for patients suffering from pain and dysfunction caused by cartilage defects in the knee." He added that MACI Arthro has the potential to significantly increase penetration into the largest segment of the MACI addressable market and will support sustained top-tier revenue growth for the company in the years ahead.
MACI Arthro stands out as the only restorative biologic cartilage repair product currently approved for arthroscopic administration.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Minimally Invasive Sacroiliac Joint Fusion Technique Developed by East Texas Surgeon

Dr. Babajide Ogunseinde received FDA approval for a novel posterior medial to lateral technique to treat sacroiliac joint dysfunction, offering a less invasive option.
The procedure involves a small 2 cm incision and a 3D-printed implant to stabilize and fuse the sacroiliac joints, minimizing soft tissue trauma and blood loss.

Maxx Orthopedics Gains FDA Clearance for Medial Congruent Insert in Total Knee Arthroplasty

Maxx Orthopedics has received FDA clearance for its medial congruent insert designed for use with the Freedom total knee arthroplasty system.
The new insert aims to replicate natural knee kinematics and enhance medial stability for patients undergoing total knee arthroplasty.

Acuitive Technologies' Citrepore Receives FDA Clearance for Bone Void Filling

Acuitive Technologies has received FDA 510(k) clearance for Citrepore, a synthetic bioactive bone void filler designed for orthopedic applications.
Citrepore's unique composition promotes natural bone healing by leveraging citrate, a key component in bone metabolism and formation.

Exactech Receives FDA Clearance for Truliant Porous 3D Tibial Knee Implant

Exactech's Truliant porous 3D tibial tray received FDA 510(k) clearance, marking a significant advancement in cementless knee replacement solutions.
The implant utilizes additive manufacturing to create a porous structure that mimics cancellous bone, promoting initial and biological fixation for active patients.

Exactech's Truliant Porous 3D Tibial Implant Receives FDA Clearance for Knee Replacement

Exactech has secured FDA 510(k) clearance for its Truliant® Porous 3D Tibial Tray, an innovative 3D-printed tibial knee implant designed for cementless fixation.
The Truliant Porous implant mimics cancellous bone structure, promoting initial and biological fixation, catering to active patients needing total knee arthroplasty.

Exactech's Truliant Porous 3D Tibial Implant Receives FDA Clearance for Knee Replacement

Exactech has secured FDA 510(k) clearance for its Truliant Porous Tibial Tray, a 3D-printed tibial knee implant designed for cementless fixation.
The Truliant Porous implant mimics cancellous bone structure, promoting initial and biological fixation for active patients undergoing total knee replacement.

Nature Cell's JointStem Receives FDA RMAT Designation for Severe Osteoarthritis

Nature Cell's JointStem, a stem cell therapy for severe degenerative arthritis, has been granted RMAT designation by the FDA.
The RMAT designation expedites the development and approval process for regenerative treatments targeting serious diseases with unmet medical needs.

CytexOrtho's ReNew Hip Implant Receives FDA Clearance for First-in-Human Trial

CytexOrtho has received FDA IDE approval to begin Phase 1 clinical trials for its ReNew Hip Implant, an absorbable device designed for patients with hip disease.
The ReNew Hip Implant, utilizing 3D manufacturing and polycaprolactone (PCL), aims to restore the joint’s anatomical contour through natural tissue regeneration.

Corin's Unity Knee Medial Constrained Tibial Insert Receives FDA Clearance for TKA

Corin has received FDA 510(k) clearance for its Unity Knee medial constrained tibial insert, designed for both standard and robotic-assisted total knee arthroplasty (TKA).
The Unity Knee MC insert is compatible with Corin's ApolloKnee robotic platform, allowing surgeons to stabilize the medial compartment during TKA procedures.

Regenity Biosciences' RejuvaKnee Implant Receives FDA Clearance for Meniscal Repair

Regenity Biosciences has received FDA 510(k) clearance for RejuvaKnee, a regenerative implant for soft tissue injuries of the meniscus, offering a minimally invasive, collagen-based approach.
Animal studies demonstrated that RejuvaKnee facilitated significant tissue regeneration, allowing full weight bearing within three months, surpassing outcomes of meniscectomy and allograft transplantation.

Reference News

[1]
FDA Approves Arthroscopic Knee Cartilage Repair - Orthopedics This Week
ryortho.com · Sep 12, 2024

FDA approves arthroscopic delivery of MACI®, an autologous cultured chondrocytes on porcine collagen membrane, for knee ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy